Stroke risks in women with dysmenorrhea by age and stroke subtype


Autoři: Ming-Hung Lin aff001;  Chung-Hsin Yeh aff003;  Chih-Hsin Mou aff006;  Ya-Wen Lin aff001;  Pei-Chun Chen aff001;  Yin-Yi Chang aff008;  Fung-Chang Sung aff006;  Jong-Yi Wang aff009
Působiště autorů: Department of Public Health, China Medical University, Taichung, Taiwan aff001;  Department of College Pharmacy and Health Care, Tajen University, Pintung, Taiwan aff002;  Department of Neurology, Yuan Rung Hospital, Changhua, Taiwan aff003;  Department of Nursing, College of Nursing and Health Sciences, Da-Yeh University, Changhua, Taiwan aff004;  Department of Nursing, College of Medicine and Nursing, Hungkuang University, Taichung, Taiwan aff005;  Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan aff006;  School of Nursing and Graduate Institute of Nursing, China Medical University, Taichung, Taiwan aff007;  Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan aff008;  Department of Health Service Administration, China Medical University, Taichung, Taiwan aff009
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225221

Souhrn

Background

Dysmenorrhea and stroke are health problems affecting women worldwide in their day-to-day lives; however, there is limited knowledge of the stroke risk in women with dysmenorrhea, and there have been no studies assessing the specific distribution of stroke subtypes. This case-control study assessed stroke subtypes by age and the role of comorbidities in women with dysmenorrhea.

Methods and findings

Data obtained between 1997 and 2013 from Taiwan’s health insurance database identified 514 stroke cases and 31,201 non-stroke controls in women with dysmenorrhea aged 15–49 years. Proportional distributions of subtypes and odds ratios (ORs) of stroke associated with comorbidities by age and subtype were measured. We found that the stroke risk in dysmenorrheal patients increased with age, and that hypertension was nine-fold more prevalent in the stroke cases than in the controls and was associated with an adjusted OR of 4.53 (95% confidence interval (CI) = 3.46–5.92) for all stroke cases. Moreover, the proportion of hemorrhagic stroke was greater than that of ischemic stroke in younger dysmenorrheal patients between 15–24 years old (50.5% vs. 11.4%), whereas this was reversed in those aged 30–49 years old (16.1% vs. 21.0%). Overall, 25.3% of the stroke cases consisted of transient cerebral ischemia and 31.3% were other acute but ill-defined cerebrovascular diseases, in which the prevalence increased with age for both types of strokes. Hypertension was the comorbidity with the highest OR associated with each subtype stroke; diabetes, hyperlipidemia, arrhythmia, and thyroid disease were also comorbidities that were significantly associated with ill-defined cerebrovascular diseases.

Conclusions

The stroke type varies by age in dysmenorrheal patients, and hypertension is the most important comorbidity associated with all types of stroke; therefore, more attention for stroke prevention must be paid to women with dysmenorrhea, particularly when combined with comorbidities.

Klíčová slova:

Cerebrovascular diseases – Hemorrhagic stroke – Hypertension – Ischemic stroke – stroke – Thyroid – Women's health – Dysmenorrhoea


Zdroje

1. Habibi N, Huang MSL, Gan WY, Zulida R, Safavi SM. Prevalence of primary dysmenorrhea and factors associated with its intensity among undergraduate students: a cross-sectional study. Pain Manag Nurs. 2015;16: 855–61. doi: 10.1016/j.pmn.2015.07.001 26328887

2. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics. 1981; 68:661–4. 7312467

3. Royal College of Obstetricians and Gynaecologists. The initial management of chronic pelvic pain. Green-top Guideline No. 41. London (UK): RCOG; 2012. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_41.pdf. Retrieved 3/15/2019.

4. Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med. 2010;363: 365–71. doi: 10.1056/NEJMcp0912024 20660404.

5. Schisterman EF, Gaskins AJ, Mumford SL, Browne RW, Yeung E, Trevisan M, et al. Influence of endogenous reproductive hormones on F2-isoprostane levels in premenopausal women: the BioCycle Study. Am J Epidemiol. 2010;172: 430–9. doi: 10.1093/aje/kwq131 20679069.

6. Kische H, Gross S, Wallaschofski H, Volzke H, Dorr M, Nauck M, et al. Clinical correlates of sex hormones in women: The study of health in Pomerania. Metabolism. 2016;65:1286–96. doi: 10.1016/j.metabol.2016.05.011 27506736.

7. Xu H, Li PH, Barrow TM, Colicino E, Li C, Song R, Liu H, et al. Obesity as an effect modifier of the association between menstrual abnormalities and hypertension in young adult women: Results from Project ELEFANT. PLoS One. 2018;13: e0207929. doi: 10.1371/journal.pone.0207929 30485368

8. Mu F, Rich-Edwards J, Rimm EB, Spiegelman D, Forman JP, Missmer SA. Association between endometriosis and hypercholesterolemia or hypertension. Hypertension. 2017;70: 59–65. doi: 10.1161/HYPERTENSIONAHA.117.09056 28559401

9. Harada T. Dysmenorrhea and Endometriosis in Young Women. Yonago Acta Medica. 2013;56: 81–84. 24574576

10. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2006;31: 565–76. doi: 10.1111/j.1365-2710.2006.00774.x 17176361

11. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008; 372:1756–64. doi: 10.1016/S0140-6736(08)61490-7 18922570

12. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79. doi: 10.1016/S0140-6736(13)60900-9 PMC 3778977. 23726390

13. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archi Inter Med. 2009;169: 141–149. doi: 10.1001/archinternmed.2008.525 19171810

14. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383: 245–54. doi: 10.1016/s0140-6736(13)61953-4 24449944

15. Hsing AW, Ioannidis JPA. Lessons from the Taiwan National Health Insurance research. JAMA Intern Med. 2015;175: 1527−9. doi: 10.1001/jamainternmed.2015.3540 26192815

16. Aiyagari V, Gorelick PB. (Eds.) Hypertension and stroke: Pathophysiology and management. Humana Press, 2016.

17. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120: 472–495. doi: 10.1161/CIRCRESAHA.116.308398 28154098

18. Zanchetti A, Liu L., Mancia G, Parati G, Grassi G, Stramba-Badiale M, Scotti L. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension–Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens. 2014;32: 1888–1897. doi: 10.1097/HJH.0000000000000254 24979303

19. De Sanctis V, Soliman AT, Elsedfy H, Soliman NA, Soliman R, El Kholy M. Dysmenorrhea in adolescents and young adults: a review in different country. Acta Biomed. 2017;87: 233–246. 28112688

20. Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol. Rev. 2013; 36: 104–113. doi: 10.1093/epirev/mxt009 24284871

21. Chen PC, Chien KL, Chang CW, Su TC, Jeng JS, Lee YT, Sung FC. More Hemorrhagic and Severe Events Cause Higher Hospitalization Care Cost for Childhood Stroke in Taiwan. J Pediatr. 2008;152: 388–393. doi: 10.1016/j.jpeds.2007.08.003 18280847

22. Lynch JK, Hirtz DG, De Veber G, Nelson KB. Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics. 2002;109: 116–123. doi: 10.1542/peds.109.1.116 11773550

23. Chung B, Wong V. Pediatric stroke among Hong Kong Chinese subjects. Pediatric. 2004;114: e206–212.

24. Giroud M, Lemesle M, Gouyon JB, Nivelon JL, Milan C, Dumas R. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: A study of incidence and clinical feature from 1985–1993. J Clin Epidemiol. 1995;48: 1343–8. doi: 10.1016/0895-4356(95)00039-9 7490597

25. Lai YJ, Chen HC, Chou P. Gender difference in the interaction effects of diabetes and hypertension on stroke among the elderly in the Shih-Pai Study, Taiwan. Plos one. 2015;10: e0136634. doi: 10.1371/journal.pone.0136634 26322779

26. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review. Headache. 2018;58: 5–21. doi: 10.1111/head.13229 29139115

27. Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47: 1734–41. doi: 10.1161/STROKEAHA.116.013052 116.013052. Epub 2016 Jun 2. 27256671

28. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37: 1725–30. doi: 10.1161/01.STR.0000226642.55207.94 16728684

29. Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10: 25–32. doi: 10.2147/VHRM.S54159 24421643

30. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357: j1909. doi: 10.1136/bmj.j1909 28487435


Článek vyšel v časopise

PLOS One


2019 Číslo 11